Investment & Business

Leading voices from Investment & Business

EYENOVATE & Retina Futura Clinical Trials 2026

Discovering the Speakers and Panelists

Houman Hemmati, MD, PhD

Co-Founder and Chief Medical Officer of Optigo Biotherapeutics

A board-certified ophthalmologist and physician-scientist, he previously led clinical development programs at Allergan (including Restasis X and the Vuity presbyopia program that achieved FDA approval) and new therapies at Capricor Therapeutics. He holds an MD from UCLA and PhD in Biology from Caltech (MSTP), with residency at the Wilmer Eye Institute at Johns Hopkins, postdoctoral training in drug delivery with Robert Langer at MIT, and cornea/refractive fellowship at Harvard’s Massachusetts Eye & Ear; he serves as voluntary adjunct faculty at the USC Keck School of Medicine while advising multiple ophthalmic companies on anterior and posterior segment drug development.

Lili Nsongo PhD, MBA

Leerink Partners

Lili Nsongo is an Equity Research Analyst at Leerink Partners, focusing on Genetic Medicines, including gene therapy and RNA technologies. Prior to Leerink, Lili led Research & Innovation at Delos, a health-tech startup developing algorithms and solutions for health outcome prediction and optimization. Lili holds a PhD in Neurobiology & Neurosciences from the Mayo Clinic, an MBA from Purdue University, and a BS of Genetics from the European Magister of Genetics at Paris Diderot.  

Paola Pozzi

Partner, Sofinnova Telethon Fund at Sofinnova Partners

Paola is since 2018 a partner with the Sofinnova Telethon Fund, Italy’s first biotechnology fund focused on rare and genetic diseases. Prior to that, she was head of the Office of Biotechnology Transfer of Ospedale San Raffaele, an internationally renowned research hospital based in Milan, where she spent 14 years actively promoting and contributing to scouting, protecting and licensing intellectual property, including through the incorporation of start-ups.
Paola got a master’s degree in intellectual property law before heading up the patent portfolio at St. Raffaele.
Prior to her time at San Raffaele, Paola spent more than 2 years working at The National Institutes of Health in Bethesda, Maryland, studying neurobiology using RNA interference.
She holds a degree in pharmaceutical biotechnology from the University of Milan and a master’s in Intellectual Property Law from the Just Legal Services, a legal training school in Milan.

Monica Volpin

Principal Life Science, Neva SGR

Monica Volpin is a Principal in the Life Science investment team at NEVA SGR, the venture capital arm of Intesa Sanpaolo Group, where her investment activity spans both Europe and the US. Monica brings more than 10 years of experience in the life sciences sector, with a focus on gene therapy and viral vectors. She holds a Ph.D. in Molecular Medicine from San Raffaele University in Milan and an Executive MBA from SDA Bocconi School of Management.

Join us for a unique, multidisciplinary forum with leading industry, investor, and clinical care innovators.